Bomedemstat
drugOn this page
Also known as Img-7289
Summary
Bomedemstat (CHEMBL4297289) is a phase-3 clinical-stage small molecule; indicated across 7 conditions including essential thrombocythemia and acquired polycythemia vera.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 7 conditions
- Clinical trials: 16
- Chemistry: 519.6 Da · C28H34FN7O2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297289 |
| Name | Bomedemstat |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 122460381 |
| Molecular formula | C28H34FN7O2 |
| Molecular weight | 519.6 |
| InChIKey | KQKBMHGOHXOHTD-KKUQBAQOSA-N |
SMILES: CN1CCN(CC1)C(=O)[C@H](CCCN[C@@H]2C[C@H]2C3=CC=C(C=C3)F)NC(=O)C4=CC=C(C=C4)N5C=CN=N5
IUPAC name: N-[(2S)-5-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(triazol-1-yl)benzamide
Also known as: Bomedemstat, Img-7289, IMG-7289, BOMEDEMSTAT
Parent form; salt/anhydrous children: CHEMBL5095405
Patent coverage: 168 distinct patent families (449 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Lysine-specific histone demethylase 1A.
Bioactivity
ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| KDM1A | 7.25 | IC50 | 56.8 | nM | CHEMBL_ACT_25480391 |
| KDM1A | 5 | IC50 | 10000 | nM | CHEMBL_ACT_27836954 |
| KDM1A | 5 | IC50 | 10000 | nM | CHEMBL_ACT_28600649 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| essential thrombocythemia | 3 | MONDO:0005029 | EFO:0000479 |
| acquired polycythemia vera | 2 | MONDO:0009891 | EFO:0002429 |
| primary myelofibrosis | 2 | MONDO:0009692 | MONDO:0044903 |
| myelodysplastic syndrome | 1 | MONDO:0018881 | EFO:0000198 |
| acute myeloid leukemia | 1 | MONDO:0018874 | EFO:0000222 |
| small cell lung carcinoma | 1 | MONDO:0008433 | EFO:0000702 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
Clinical trials
Total trials: 16.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 7 |
| PHASE3 | 3 |
| PHASE1/PHASE2 | 3 |
| PHASE1 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06079879 | PHASE3 | RECRUITING | A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) |
| NCT06351631 | PHASE3 | RECRUITING | A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) |
| NCT06456346 | PHASE3 | RECRUITING | Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) |
| NCT04081220 | PHASE2 | ACTIVE_NOT_RECRUITING | Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2 |
| NCT04262141 | PHASE2 | ACTIVE_NOT_RECRUITING | IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) |
| NCT07424950 | PHASE2 | NOT_YET_RECRUITING | Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis |
| NCT02842827 | PHASE1/PHASE2 | COMPLETED | A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001) |
| NCT03136185 | PHASE1/PHASE2 | COMPLETED | Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) |
| NCT04254978 | PHASE2 | COMPLETED | Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003) |
| NCT05191797 | PHASE1/PHASE2 | TERMINATED | Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer |
| NCT05223920 | PHASE2 | COMPLETED | An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) |
| NCT05558696 | PHASE2 | COMPLETED | A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004) |
| NCT05569538 | PHASE2 | UNKNOWN | Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis |
| NCT05597306 | PHASE1 | RECRUITING | Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
| NCT06596668 | PHASE1 | COMPLETED | Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020) |
| NCT07049939 | PHASE1 | COMPLETED | A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: essential thrombocythemia